Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oculis Holding AG - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
OCS
Nasdaq
2830
oculis.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oculis Holding AG
We're Hopeful That Oculis Holding (NASDAQ:OCS) Will Use Its Cash Wisely
- Feb 6th, 2025 11:07 am
Oculis updates share capital for its existing at-the-market offering program
- Jan 31st, 2025 9:00 pm
Oculis Trial Shows Potential for Optical Neuroprotective Therapy
- Jan 6th, 2025 10:30 pm
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
- Jan 6th, 2025 8:53 am
Oculis to Present at the Stifel 2024 Healthcare Conference
- Nov 13th, 2024 9:00 am
Oculis Holding Third Quarter 2024 Earnings: Misses Expectations
- Nov 8th, 2024 10:09 am
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
- Nov 7th, 2024 9:00 am
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%
- Oct 30th, 2024 3:12 pm
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
- Oct 21st, 2024 5:04 pm
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
- Oct 15th, 2024 8:00 am
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
- Oct 2nd, 2024 8:00 am
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
- Sep 19th, 2024 5:00 pm
Oculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth Plans
- Aug 30th, 2024 10:40 am
Oculis to Present at Upcoming September Investor Conferences
- Aug 29th, 2024 8:00 am
Oculis Reports Q2 Financial Results and Provides Recent Company Update
- Aug 27th, 2024 8:00 am
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
- Aug 27th, 2024 8:00 am
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
- Aug 15th, 2024 12:00 pm
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Jul 30th, 2024 8:10 pm
Oculis and EURETINA Announces the Ramin Tadayoni Award
- Jun 27th, 2024 10:30 am
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
- Jun 10th, 2024 9:00 am
Scroll